The Influence of Chlorella Supplementation on Running Performance
Launched by UNIVERSITY COLLEGE, LONDON · Jun 24, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether taking a daily supplement of chlorella, a type of green algae, can improve running performance in regular runners. Chlorella is known for being packed with nutrients that may help boost health and athletic ability. The research will focus on how it affects different aspects of running during both easy and intense workouts. The study will last for three weeks, and participants will take either chlorella or a placebo (a harmless dummy pill) without knowing which one they received.
To be eligible for the trial, participants should be between 18 and 50 years old, run regularly (about 3 to 4 times a week) with the goal of competing, and be part of a local running club. They should also be comfortable running for over 30 minutes at a moderate pace. However, individuals who are on blood thinners, have allergies to algae or iodine, have certain health conditions, or are taking immunosuppressant medications cannot participate. This is a great opportunity for runners looking to possibly enhance their performance while contributing to important research!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged 18-50.
- • Run regularly (3-4 times a week).
- • Train with a purpose to compete.
- • Consider running to be your main sport.
- • Be comfortable running continuously for over 30-minutes at moderate intensity.
- • Represent a local running club.
- Exclusion Criteria:
- • Individuals taking blood thinners.
- • Known allergies to algae/mould and iodine.
- • Any illness/conditions identified on PARQ (please see attached PARQ)
- • Taking immunosuppressant medication
About University College, London
University College London (UCL) is a leading global research institution renowned for its commitment to advancing healthcare through innovative clinical trials. As a prominent sponsor of clinical research, UCL leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous investigations aimed at improving patient outcomes and addressing pressing medical challenges. The institution fosters collaboration among researchers, healthcare professionals, and industry partners, ensuring that its trials adhere to the highest ethical standards and regulatory guidelines. UCL's dedication to translating scientific discoveries into practical applications underscores its role as a vital contributor to the advancement of medical science and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Tom Gurney
Principal Investigator
University College, London
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported